Shockwave Medical, Inc.

NasdaqGS:SWAV Stock Report

Market Cap: US$12.6b

Shockwave Medical Valuation

Is SWAV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SWAV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SWAV ($334.75) is trading above our estimate of fair value ($331.27)

Significantly Below Fair Value: SWAV is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SWAV?

Other financial metrics that can be useful for relative valuation.

SWAV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue15.6x
Enterprise Value/EBITDA68.3x
PEG Ratio4.2x

Price to Earnings Ratio vs Peers

How does SWAV's PE Ratio compare to its peers?

The above table shows the PE ratio for SWAV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.9x
PODD Insulet
41.7x2.5%US$16.5b
MASI Masimo
97.1x25.1%US$7.7b
TFX Teleflex
41.2x22.8%US$9.8b
STE STERIS
39.6x13.1%US$22.2b
SWAV Shockwave Medical
76.9x18.4%US$12.6b

Price-To-Earnings vs Peers: SWAV is good value based on its Price-To-Earnings Ratio (76.9x) compared to the peer average (87.6x).

Price to Earnings Ratio vs Industry

How does SWAV's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.3%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.3%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: SWAV is expensive based on its Price-To-Earnings Ratio (76.9x) compared to the US Medical Equipment industry average (37.8x).

Price to Earnings Ratio vs Fair Ratio

What is SWAV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SWAV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio76.9x
Fair PE Ratio40.4x

Price-To-Earnings vs Fair Ratio: SWAV is expensive based on its Price-To-Earnings Ratio (76.9x) compared to the estimated Fair Price-To-Earnings Ratio (40.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SWAV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$326.05
0%
8.9%US$348.42US$250.00n/a8
Oct ’25n/a
US$326.05
0%
8.9%US$348.42US$250.00n/a8
Sep ’25n/a
US$326.05
0%
8.9%US$348.42US$250.00n/a8
Aug ’25n/a
US$326.05
0%
8.9%US$348.42US$250.00n/a8
Jul ’25n/a
US$326.05
0%
8.9%US$348.42US$250.00n/a8
Jun ’25US$334.75
US$326.05
-2.6%
8.9%US$348.42US$250.00n/a8
May ’25US$329.84
US$294.27
-10.8%
21.8%US$348.42US$165.00n/a9
Apr ’25US$320.51
US$280.12
-12.6%
20.3%US$368.00US$165.00n/a12
Mar ’25US$263.41
US$257.55
-2.2%
14.0%US$290.00US$165.00n/a11
Feb ’25US$231.78
US$232.45
+0.3%
13.2%US$275.00US$165.00n/a11
Jan ’25US$190.56
US$232.45
+22.0%
13.2%US$275.00US$165.00n/a11
Dec ’24US$182.20
US$239.91
+31.7%
13.8%US$284.00US$165.00n/a11
Nov ’24US$213.56
US$265.64
+24.4%
15.9%US$315.00US$165.00n/a11
Oct ’24US$199.10
US$278.20
+39.7%
18.0%US$330.00US$165.00n/a10
Sep ’24US$222.41
US$284.89
+28.1%
17.0%US$330.00US$165.00n/a9
Aug ’24US$259.75
US$294.78
+13.5%
16.5%US$335.00US$165.00n/a9
Jul ’24US$285.41
US$289.33
+1.4%
15.9%US$325.00US$165.00n/a9
Jun ’24US$281.66
US$289.33
+2.7%
15.9%US$325.00US$165.00US$334.759
May ’24US$288.95
US$259.67
-10.1%
16.0%US$316.00US$165.00US$329.849
Apr ’24US$216.83
US$240.89
+11.1%
15.4%US$285.00US$165.00US$320.519
Mar ’24US$189.29
US$241.00
+27.3%
16.3%US$285.00US$165.00US$263.418
Feb ’24US$191.36
US$243.25
+27.1%
16.8%US$285.00US$165.00US$231.788
Jan ’24US$205.61
US$272.50
+32.5%
19.0%US$338.00US$165.00US$190.568
Dec ’23US$252.46
US$286.86
+13.6%
18.2%US$338.00US$165.00US$182.207
Nov ’23US$292.05
US$261.86
-10.3%
19.4%US$338.00US$165.00US$213.567

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y